Neogenomics INC (NEO) — SEC Filings

Overview

Neogenomics INC (NEO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 28, 2025: NEOGENOMICS INC reported a significant increase in net revenue for the three months ended September 30, 2025, reaching $187.8 million, up from $167.8 million in the prior year, representing an 11.9% increase. However, the company experienced a substantial rise in net loss, widening to $27.1 million

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 1 bearish, 30 neutral. The dominant filing sentiment for Neogenomics INC is neutral.

Filing Type Overview

Neogenomics INC (NEO) has filed 14 8-K, 4 10-Q, 1 DEFA14A, 3 8-K/A, 2 10-K, 2 SC 13G, 4 SC 13G/A, 1 DEF 14A with the SEC between Jan 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (31)

• 8-K Filing — 8-K · Dec 30, 2025
• NeoGenomics Revenue Up, But Losses Widen Amid Impairment Charges — 10-Q · Oct 28, 2025 Risk: high
  NEOGENOMICS INC reported a significant increase in net revenue for the three months ended September 30, 2025, reaching $187.8 million, up from $167.8 million in
• NeoGenomics Announces Board Changes — 8-K · Aug 8, 2025 Risk: low
  On August 5, 2025, NeoGenomics, Inc. announced the departure of Director Dr. Jonathan R. Rothberg and the election of new Director Dr. David J. Halbert. The com
• NeoGenomics Inc. Files 8-K on Financials — 8-K · Jul 29, 2025 Risk: low
  On July 29, 2025, NeoGenomics Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fi
• NeoGenomics Board Shake-up: Two Directors Depart, Two New Ones Elected — 8-K · Jun 24, 2025 Risk: medium
  On June 19, 2025, NeoGenomics, Inc. filed an 8-K report detailing the departure of two directors, Mark Goldsmith and Robert Lamy, effective June 17, 2025. The c
• NeoGenomics Files 8-K: Officer Departures, Director Elections — 8-K · May 27, 2025 Risk: medium
  On May 22, 2025, NeoGenomics, Inc. filed an 8-K report detailing the departure of certain officers and the election of new directors. The filing also covers the
• NeoGenomics Q1 2025 Financials Filed — 10-Q · Apr 29, 2025 Risk: medium
  NeoGenomics Inc. reported its first quarter results for the period ending March 31, 2025. The company's filing details its financial position, including common
• NeoGenomics Files Proxy Materials — DEFA14A · Apr 23, 2025 Risk: low
  NeoGenomics Inc. filed a Definitive Additional Materials proxy statement on April 23, 2025. This filing is related to their annual meeting and likely contains i
• NeoGenomics Files 8-K for Bylaw, Charter Amendments — 8-K · Apr 8, 2025 Risk: low
  On April 4, 2025, NeoGenomics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and Bylaws. The filing also includes financial sta
• NeoGenomics Files 8-K/A Amendment on Officer/Director Changes — 8-K/A · Mar 31, 2025 Risk: low
  NeoGenomics, Inc. filed an amendment (8-K/A) on March 31, 2025, to its report originally dated January 3, 2025. This amendment pertains to the departure of dire
• NeoGenomics Files 8-K/A Amendment on Officer Compensation — 8-K/A · Mar 19, 2025 Risk: low
  NeoGenomics, Inc. filed an 8-K/A on March 19, 2025, to amend its previous filing regarding the departure of certain officers and the election of directors. The
• NeoGenomics Reports Director Changes and Officer Compensation Adjustments — 8-K · Mar 18, 2025 Risk: medium
  On March 18, 2025, NeoGenomics Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the electio
• Neogenomics Inc. Files 2024 10-K — 10-K · Feb 18, 2025 Risk: medium
  Neogenomics Inc. filed its 2024 10-K on February 18, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Nevada and headqu
• NeoGenomics Announces Leadership Changes and Compensatory Arrangements — 8-K · Jan 15, 2025 Risk: medium
  On January 14, 2025, NeoGenomics, Inc. announced the departure of Director Dr. Jonathan R. Rothberg and the appointment of Dr. David M. Goldenberg as Chief Medi
• NeoGenomics Announces Board and Executive Changes — 8-K · Jan 10, 2025 Risk: medium
  On January 3, 2025, NeoGenomics, Inc. announced changes in its board of directors and executive compensation. The company filed an 8-K report detailing the depa
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• NeoGenomics Files 8-K: Operations, Board & Officer Changes — 8-K · Nov 5, 2024 Risk: medium
  On November 1, 2024, NeoGenomics, Inc. filed an 8-K report detailing significant corporate events. The filing includes information regarding the company's resul
• NeoGenomics Q2 2024: $235.7M Revenue, $36.7M Net Loss — 10-Q · Jul 30, 2024 Risk: medium
  NeoGenomics Inc. reported its Q2 2024 results, with total revenue for the six months ended June 30, 2024, reaching $235.7 million. The company's net loss for th
• NeoGenomics Inc. Files 8-K on Financials — 8-K · Jul 29, 2024 Risk: low
  On July 29, 2024, NeoGenomics Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fi
• NeoGenomics Holds Annual Stockholder Meeting — 8-K · May 24, 2024 Risk: low
  On May 23, 2024, NeoGenomics, Inc. filed an 8-K report to announce the results of its annual meeting of stockholders. The company's stockholders voted on severa
• NeoGenomics, Inc. Reports First Quarter 2024 Financial Results — 10-Q · Apr 30, 2024 Risk: medium
  NEOGENOMICS INC (NEO) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Revenue for the three months ended March 31, 2024, was $126.9 million. Net
• NeoGenomics Appoints New CEO, Dr. Mark Mallon — 8-K · Apr 18, 2024 Risk: medium
  On April 15, 2024, NeoGenomics Inc. announced the appointment of Dr. Mark Mallon as Chief Executive Officer and a member of the Board of Directors, effective im
• NEOGENOMICS INC Files DEF 14A with Executive Compensation Details — DEF 14A · Apr 8, 2024 Risk:
  NEOGENOMICS INC (NEO) filed a Proxy Statement (DEF 14A) with the SEC on April 8, 2024. Filing is a Definitive Proxy Statement (DEF 14A) for the fiscal year endi
• NeoGenomics Amends 8-K Filing on Officer Changes and Compensation — 8-K/A · Feb 26, 2024 Risk: low
  NEOGENOMICS INC filed an 8-K/A on February 26, 2024, amending a previous report from February 16, 2024. The filing pertains to Item 5.02, "Departure of Director
• NeoGenomics Grants Performance Share Units to Officers — 8-K · Feb 23, 2024 Risk: low
  NeoGenomics, Inc. filed an 8-K on February 23, 2024, reporting on compensatory arrangements for certain officers, specifically the grant of Performance Share Un
• Neogenomics Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 20, 2024 Risk: medium
  NEOGENOMICS INC (NEO) filed a Annual Report (10-K) with the SEC on February 20, 2024. Neogenomics Inc. filed its 2023 Form 10-K on February 20, 2024. The filing
• SC 13G Filing — SC 13G · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Brown Advisory Amends NEO Stake, Confirms Continued Investment — SC 13G/A · Feb 9, 2024 Risk: low
  Brown Advisory Inc. filed an amended SC 13G/A on February 9, 2024, indicating its ownership of NeoGenomics, Inc. (NEO) shares as of December 31, 2023. This fili
• BlackRock Amends NeoGenomics Stake to 9.5% as of Dec 31, 2023 — SC 13G/A · Jan 22, 2024
  BlackRock Inc. has filed an amended Schedule 13G/A, indicating a change in its ownership stake in NEOGENOMICS INC. As of December 31, 2023, BlackRock Inc. repor

Risk Profile

Risk Assessment: Of NEO's 24 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Neogenomics INC's most recent 10-Q filing (Oct 28, 2025):

• Revenue: $537.2M
• Net Income: -$98.1M
• EPS: -$0.77
• Debt-to-Equity: 0.64
• Cash Position: $164.1M
• Operating Margin: -19.1%
• Total Assets: $1,374.8M
• Total Debt: $879.1M

Key Executives

• Dr. Jonathan R. Rothberg
• Dr. David J. Halbert
• Mark Goldsmith
• Robert Lamy
• David H. Smith
• Robert L. W. Smith
• Dr. David M. Goldenberg
• Dr. Mark Mallon
• Dr. Jeffrey Miller
• Dr. Steven B. Johnson
• Christopher Smith
• Lynn Tetrault
• Mark Mallon
• Douglas VanOort

Industry Context

NeoGenomics operates in the oncology diagnostics sector, providing specialized testing and interpretation services. The industry is characterized by rapid technological advancements, increasing demand for personalized medicine, and a competitive landscape with both large players and niche providers. Regulatory scrutiny and reimbursement policies are also key factors influencing market dynamics.

Top Tags

executive-compensation (7) · amendment (5) · corporate-governance (5) · governance (4) · financials (4) · board-changes (3) · leadership-change (3) · financial-reporting (2) · 8-k (2) · 10-Q (2)

Executive Compensation

From the most recent DEF 14A filing (Apr 8, 2024):

• Christopher Smith — Member
• Lynn Tetrault — Member
• Mark Mallon — Member

Key Numbers

• Net Revenue (Q3 2025): $187.8M — Increased from $167.8M in Q3 2024, an 11.9% rise.
• Net Loss (Q3 2025): $27.1M — Widened from $17.7M in Q3 2024, a 53.1% increase in loss.
• Net Revenue (YTD Sept 2025): $537.2M — Increased from $488.6M in YTD Sept 2024, a 9.9% rise.
• Net Loss (YTD Sept 2025): $98.1M — Widened from $63.4M in YTD Sept 2024, a 54.7% increase in loss.
• Cash and Cash Equivalents: $164.1M — Decreased from $367.0M at Dec 31, 2024, a 55.3% reduction.
• Repayment of Convertible Debt: $201.3M — Major cash outflow in financing activities for YTD Sept 2025.
• Impairment Charges: $27.1M — Recognized for the nine months ended Sept 30, 2025, impacting profitability.
• Basic Net Loss Per Share (Q3 2025): $0.21 — Increased from $0.14 in Q3 2024.
• Basic Net Loss Per Share (YTD Sept 2025): $0.77 — Increased from $0.50 in YTD Sept 2024.
• Self-insurance liability: $2.8M — Recorded as of September 30, 2025, for employee health care benefits.
• Commission File Number: 001-35756 — Identifies the company's SEC filing history.
• I.R.S. Employer Identification No.: 74-2897368 — Company's tax identification number.
• Reporting Period End Date: 2025-03-31 — Current quarter end
• Prior Year End Date: 2024-12-31 — Previous year's financial position
• Current Quarter Period: 2025-01-01 to 2025-03-31 — First quarter of 2025

Frequently Asked Questions